Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Onc promotional data, my read fwiw

<< Previous

Bullboard Posts

Next >>

Comment by lonc17on Dec 11, 2022 4:41pm

208 Views

Post# 35164948

RE:Onc promotional data, my read fwiw

Buyer beware, Canadafan.

There have been many instances in the past when these advertisments have been used soley to pump ONC's ATM.

The worst culprit of all is Edison Investment Research.

The moment that ONC buys another of their "research" reports will a sad day for the company.

Becuase it will tell us with certaninty that ONC has been rejected by potential partners.

As of now, I hope for the best. But this behavior is very unbecoming for a rising star such as ONC!